About
Overview
Leadership
Area of Focus
Congestion in Heart Failure
Outpatient Parenteral Antimicrobial Treatment (OPAT)
Research and Development
FUROSCIX
®
(furosemide injection) for subcutaneous administration
scCeftriaxone
Clinical Development & Medical Affairs
Investor Relations
Investor Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Corporate Governance
Governance Highlights
Committee Composition
Financial Information
Sec Filings
News & Events
News Releases
Event Calendar
Presentations
Investor Resources
Investor FAQ
Information Request
E-mail Alerts
Ir Contacts
Media Resources
Careers
Contact Us
Legal
Privacy Policy
Terms of Use
scPharmaceuticals
Areas of Focus
Research & Development
Careers
Recent News
July 13, 2021
scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study
Read More
July 01, 2021
scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX
®
Read More
May 19, 2021
scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Read More
May 12, 2021
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
Read More
All News
